• The convergence of digital transformation and the GenAI revolution creates an unprecedented opportunity for accelerating progress in precision health. • Precision immunotherapy is a poster child for this transformation. • Emerging technologies such as multiplex immunofluorescence (mIF) can assess internal states of individual cells along with their spatial locations, which is critical for deciphering how tumors interact with the immune system. • The resulting insights, often referred to as the “grammar” of the tumor microenvironment, can help predict whether a tumor will respond to immunotherapy. • If it is unlikely to respond, these insights can also inform strategies to reprogram the tumor from “cold” to “hot,” increasing its susceptibility to treatment. • This is exciting, but progress is hindered by the high cost and limited scalability of current technology.
Article Summaries:
- GigaTIME is a multimodal AI model that converts routine H&E pathology slides into virtual multiplex immunofluorescence (mIF) images, enabling large‑scale analysis of the tumor microenvironment (TIME). Trained on 40 million paired cells from Providence and the University of Washington, the model generated ~300,000 virtual mIF images across 24 cancer types from 14,256 patients. The study identified 1,234 significant links between protein activations and clinical outcomes, and validated findings in 10,200 TCGA patients. This is the first population‑scale spatial proteomics study of TIME, offering a new framework for precision oncology research. GigaTIME is publicly available on Microsoft Foundry Labs and Hugging Face.
Sources: